Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Negative design for improved therapeutic proteins

John R Desjarlais1, Greg A Lazar

  • 1Xencor, 111 W. Lemon Avenue, Monrovia, CA 91016, USA. jrd@xencor.com

Trends in Biotechnology
|September 27, 2003
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A quantitative systems pharmacology model to inform clinical translation of dynamic PKPD relationships of engineered IL-15.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations.

EBioMedicine·2025
Same author

Leveraging neonatal Fc receptor (FcRn) to enhance antibody transport across the blood brain barrier.

Nature communications·2025
Same author

A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies.

Molecular cancer therapeutics·2024
Same author

Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy.

Frontiers in pharmacology·2024
Same author

i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists.

Nature communications·2024